Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 14 of 23
Tranquil Moments II-CBT vs. Yoga for Worry
NCT02968238
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
NCT03056001
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
NCT03087591
Internet-Delivered Positive Affect Program in Managing Emotion in Young Adult Cancer Survivors
NCT02832154
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
NCT02581917
Comparison of PVI Plus Catheter Ablation or PVI Alone for the Treatment of AFib for Patients With Paroxysmal Atrial Fibrillation
NCT03115554
The New Executive and Appendix Template (NEAT) Study
NCT03419832
Loss of Resistance, w/wo Stimulation, For Epidural Placement
NCT03087604
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
NCT02949843
Parents as the Primary Sexuality Educators for Their Young Adults With Down Syndrome
NCT03135236
The Urinary Incontinence Treatment Study
NCT03057834
A Review of "Anesthesia Stat!" in the Pediatric Operating Room
NCT03152513
Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer
NCT03122743
Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty
NCT02991404
Concussion Texting Study
NCT03099733
Evaluating Treatment Resistant Dermatitis TaroIIR
NCT03050294
IINB vs. QLB for Elective Open Inguinal Herniorrhaphy
NCT03007966
Mobility Assessment Using Surrogates in Elderly Participants
NCT03032341
Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery
NCT03011307
Evaluating Dysphagia in Neonates With CHD
NCT03045757
Ambient Lighting During Colonoscopy and Its Effect on Adenoma Detection Rate and Eye Fatigue
NCT04441242
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
NCT02827838
Prospective Treatment Study of Catatonia Patients
NCT02734498
Preparatory Work to Assess Adherence to Oral Chemotherapy
NCT02895542
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
NCT02874989
EMPOWER-PULM (PULMonary Outcomes in Older Adults Empowered With Movement to Prevent Obesity and Weight Regain)
NCT03621098
Empowered With Movement to Prevent Obesity and Weight Regain
NCT02923674
Comparison of Two Techniques of IV Lidocaine on Propofol Injection Pain
NCT03057704
PARA-HEART Pilot Implementation
NCT02709135
Use of Vasopressin Following the Fontan Operation
NCT02975999
Extubation in Pediatric Patients: An Observational Study
NCT02963532
Role of Polyunsaturated Fatty Acids (PUFA)-Gene Interactions in Heath Disparities
NCT02962128
Evaluation of Free Air Portable Air Powered Respirator
NCT02487147
Valued EpiGenetic Glycemic ImprovEments Through Weight Loss
NCT02869659
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02971397
Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
NCT03741868
Effectiveness of the Advocate Lutheran General Survivorship Center Programs
NCT02660996
Biologics Anchoring Study
NCT03026153
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT02612194
COcoa Supplement and Multivitamin Outcomes Study for the Mind
NCT03035201
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients
NCT03139708
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
NCT02927938
The Impact of Art Therapy on the Relationships Between Individuals Diagnosed With Alzheimer's Disease and Their Care Partners
NCT06725251
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
NCT02695498
MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment
NCT02702830
Pain Processing in Adults With Migraines
NCT02748577
Pediatric Pain Assessment in the Emergency Department
NCT03157882
Genomic Outcomes of Metformin
NCT02986659
The TREND Study: Tapered Reduction in Energy Intake as a Novel Approach to Dieting
NCT02837211
Pulmonary Embolism Short-term Clinical Outcomes Registry
NCT02883491
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.